TY - GEN
T1 - Correction to "The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP" [Oncotarget. 2017; 8:17038-17049]. https://doi.org/10.18632/oncotarget.14928
AU - Jung, Hyunchul
AU - Yoo, Hae Yong
AU - Lee, Seung Ho
AU - Shin, Sohyun
AU - Kim, Sang Cheol
AU - Lee, Sejoon
AU - Joung, Je Gun
AU - Nam, Jae Yong
AU - Ryu, Daeun
AU - Yun, Jae Won
AU - Choi, Jung Kyoon
AU - Ghosh, Ambarnil
AU - Kim, Kyeong Kyu
AU - Kim, Seok Jin
AU - Kim, Won Seog
AU - Park, Woong Yang
AU - Ko, Young Hyeh
PY - 2018/8/28
Y1 - 2018/8/28
N2 - This article has been corrected: The correct order of author affiliations is given below: Hyunchul Jung1,4,*, Hae Yong Yoo2,*, Seung Ho Lee2,*, Sohyun Shin3, Sang Cheol Kim4, Sejoon Lee4, Je-Gun Joung4, Jae-Yong Nam2,4, Daeun Ryu2,4, Jae Won Yun4,5, Jung Kyoon Choi1, Ambarnil Ghosh5, Kyeong Kyu Kim5, Seok Jin Kim6, Won Seog Kim6, Woong-Yang Park1 and Young Hyeh Ko3 1 Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea 2 Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea 3 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 4 Samsung Genome Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea 5 Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea 6 Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea * These authors have contributed equally to this work Original article: Oncotarget. 2017; 8:17038-17049. https://doi.org/10.18632/oncotarget.14928.
AB - This article has been corrected: The correct order of author affiliations is given below: Hyunchul Jung1,4,*, Hae Yong Yoo2,*, Seung Ho Lee2,*, Sohyun Shin3, Sang Cheol Kim4, Sejoon Lee4, Je-Gun Joung4, Jae-Yong Nam2,4, Daeun Ryu2,4, Jae Won Yun4,5, Jung Kyoon Choi1, Ambarnil Ghosh5, Kyeong Kyu Kim5, Seok Jin Kim6, Won Seog Kim6, Woong-Yang Park1 and Young Hyeh Ko3 1 Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea 2 Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea 3 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 4 Samsung Genome Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea 5 Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea 6 Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea * These authors have contributed equally to this work Original article: Oncotarget. 2017; 8:17038-17049. https://doi.org/10.18632/oncotarget.14928.
UR - https://research.tus.ie/en/publications/de0f73f3-a85d-4898-80c2-3bddb98f203d
U2 - 10.18632/oncotarget.26080
DO - 10.18632/oncotarget.26080
M3 - Other contribution
C2 - 30214692
ER -